Heparanase upregulation by colonic epithelium in inflammatory bowel disease

Modern Pathology

Volumn 20, Issue 1, 2007, Pages 8-14

  Waterman, Matti ^a   Ben Izhak, Ofer ^a   Eliakim, Rami ^a   Groisman, Gabriel ^b   Vlodavsky, Israel ^c   Ilan, Neta ^c  

^a Rambam Health Care Campus ^*  (Israel)

^b HILLEL YAFFE MEDICAL CENTER   (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Epithelium; Heparanase; Immunostaining; Inflammatory bowel disease

Indexed keywords

ENOXAPARIN; HEPARANASE; HEPARIN;

ADULT; ARTICLE; CHRONIC INFLAMMATION; CLINICAL ARTICLE; COLON CROHN DISEASE; COLON MUCOSA; CONTROLLED STUDY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; FEMALE; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MALE; PATHOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; ULCERATIVE COLITIS; UPREGULATION;

ACUTE DISEASE; ADULT; COLITIS; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; FEMALE; GLUCURONIDASE; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MALE; MIDDLE AGED; UP-REGULATION;

EID: 33845684922     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.3800710     Document Type: Article

References (38)

1. Dempsey LA, Brunn GJ, Platt JL. Heparanase, a potential regulator of cell-matrix interactions. Trends Biochem Sci 2000;25:349-351.
2. Parish CR, Freeman C, Hulett MD. Heparanase: a key enzyme involved in cell invasion. Biochim Biophys Acta 2001;1471:M99-M108.
3. Vlodavsky I, Friedmann Y. Molecular properties and involvement of heparanase in cancer metastasis and angiogenesis. J Clin Invest 2001;108:341-347.
4. Bernfield M, Gotte M, Park PW, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 1999;68:729-777.
5. Kjellen L, Lindahl U. Proteoglycans: structures and interactions. Annu Rev Biochem 1991;60:443-475.
6. Matzner Y, Bar-Ner M, Yahalom J, et al. Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes. J Clin Invest 1985;76:1306-1313.
7. Nakajima M, Irimura T, DiFerrante D, et al. Heparan sulfate degradation: relation to tumor invasion and metastatic properties of mouse B 16 melanoma sublines. Science (Washington, DC) 1983;220:611-613.
8. Nakajima M, Irimura T, Di Ferrante N, et al. Metastatic melanoma cell heparanase. Characterization of heparan sulfate degradation fragments produced by B16 melanoma endoglucuronidase. J Biol Chem 1984;259:2283-2290.
9. Vlodavsky I, Fuks Z, Bar-Ner M, et al. Lymphoma cells mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: relation to tumor cell metastasis. Cancer Res 1983;43:2704-2711.
10. Edovitsky E, Elkin M, Zcharia E, et al. Heparanase gene silencing, tumor invasiveness, angiogenesis, and metastasis. J Natl Cancer Inst 2004;96:1219-1230.
11. Lider O, Baharav E, Mekori YA, et al. Suppression of experimental autoimmune diseases and prolongation of allograft survival by treatment of animals with low doses of heparins. J Clin Invest 1989;83:752-756.
12. Naparstek Y, Cohen IR, Fuks Z, et al. Activated T lymphocytes produce a matrix-degrading heparan sulphate endoglycosidase. Nature 1984;310:241-244.
13. Vlodavsky I, Eldor A, Haimovitz-Friedman A, et al. Expression of heparanase by platelets and circulating cells of the immune system: possible involvement in diapedesis and extravasation. Invas Metast 1992;12:112-127.
14. Vaday GG, Lider O. Extracellular matrix moieties, cytokines, and enzymes: dynamic effects on immune cell behavior and inflammation. J Leukoc Biol 2000;67:149-159.
15. Friedmann Y, Vlodavsky I, Aingorn H, et al. Expression of heparanase in normal, dysplastic, and neoplastic human colonic mucosa and stroma. Evidence for its role in colonic tumorigenesis. Am J Pathol 2000;157:1167-1175.
16. Nobuhisa T, Naomoto Y, Ohkawa T, et al. Heparanase expression correlates with malignant potential in human colon cancer. J Cancer Res Clin Oncol 2005;131:229-237.
17. Doviner V, Maly B, Kaplan V, et al. Spatial and temporal heparanase expression in colon mucosa throughout the adenoma-carcinoma sequence. Mod Pathol 2006;19:878-888.
18. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 2003;3:521-533.
19. Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6:8-15.
20. Zetser A, Levy-Adam F, Kaplan V, et al. Processing and activation of latent heparanase occurs in lysosomes. J Cell Sci 2004;117:2249-2258.
21. Levy-Adam F, Miao HQ, Heinrikson RL. Heterodimer formation is essential for heparanase enzymatic activity. Biochem Biophys Res Commun 2003;308:885-891.
22. Goldshmidt O, Nadav L, Aingorn H, et al. Human heparanase is localized within lysosomes in a stable form. Exp Cell Res 2002;281:50-62.
23. Nadav L, Eldor A, Yacoby-Zeevi O, et al. Activation, processing and trafficking of extracellular heparanase by primary human fibroblasts. J Cell Sci 2002;115:2179-2187.
24. McKenzie E, Young K, Hircock M, et al. Biochemical characterization of the active heterodimer form of human heparanase (Hpa1) protein expressed in insect cells. Biochem J 2003;373:423-435.
25. Hanauer SB. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 2006;12(Suppl 1):S3-S9.
26. Bamias G, Nyce MR, De La Rue SA, et al. New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med 2005;143:895-904.
27. Mollinedo F, Nakajima M, Llorens A, et al. Major co-localization of the extracellular-matrix degradative enzymes heparanase and gelatinase in tertiary granules of human neutrophils. Biochem J 1997;327:917-923.
28. Bashkin P, Doctrow S, Klagsbrun M, et al. Basic fibroblast growth factor binds to subendothelial extracellular matrix and is released by heparitinase and heparin-like molecules. Biochemistry 1989;28:1737-1743.
29. Bartlett MR, Underwood PA, Parish CR. Comparative analysis of the ability of leucocytes, endothelial cells and platelets to degrade the subendothelial basement membrane: evidence for cytokine dependence and detection of a novel sulfatase. Immunol Cell Biol 1995;73:113-124.
30. Parish CR, Hindmarsh EJ, Bartlett MR, et al. Treatment of central nervous system inflammation with inhibitors of basement membrane degradation. Immunol Cell Biol 1998;76:104-113.
31. Edovitsky E, Lerner I, Zcharia E, et al. Role of endothelial heparanase in delayed-type hypersensitivity. Blood 2006;107:3609-3616.
32. Bar-Ner M, Eldor A, Wasserman L, et al. Inhibition of heparanase-mediated degradation of extracellular matrix heparan sulfate by non-anticoagulant heparin species. Blood 1987;70:551-557.
33. Vlodavsky I, Mohsen M, Lider O, et al. Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invas Metast 1994;14:290-302.
34. Miao HQ, Elkin M, Aingorn E, et al. Inhibition of heparanase activity and tumor metastasis by laminarin sulfate and synthetic phosphorothioate oligodeoxynucleotides. Int J Cancer 1999;83:424-431.
35. Ferro V, Hammond E, Fairweather JK. The development of inhibitors of heparanase, a key enzyme involved in tumour metastasis, angiogenesis and inflammation. Mini Rev Med Chem 2004;4:693-702.
36. Dotan I, Hallak A, Arber N, et al. Low-dose low-molecular weight heparin (enoxaparin) is effective as adjuvant treatment in active ulcerative colitis: an open trial. Dig Dis Sci 2001;46:2239-2244.
37. Folwaczny C, Wiebecke B, Loeschke K. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease. Am J Gastroenterol 1999;94:1551-1555.
38. Prajapati DN, Newcomer JR, Emmons J, et al. Successful treatment of an acute flare of steroid-resistant Crohn's colitis during pregnancy with unfractionated heparin. Inflamm Bowel Dis 2002;8:192-195.